Nialamide: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<div style="float: right;"> | <div style="float: right;"> | ||
[[File:Nialamide.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div> | [[File:Nialamide.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div> | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Nialamide''' ('''Niamid''', '''Niamide''', '''Nuredal''', '''Surgex''') is a non-selective, [[irreversible_inhibition|irreversible]] [[monoamine oxidase inhibitor]] (MAOI) of the [[hydrazine]] class that was used as an [[antidepressant]].<ref name="Publishing2006">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=http://books.google.com/books?id=_J2ti4EkYpkC&pg=PA2935|date=1 December 2006|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=2935–}}</ref> It was withdrawn by [[Pfizer]] several decades ago due to the risk of [[hepatotoxicity]].<ref name="Gad2012">{{cite book|author=Shayne C. Gad|title=Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition|url=http://books.google.com/books?id=AHA2g-qq6WwC&pg=PA138|date=26 April 2012|publisher=CRC Press|isbn=978-1-4398-4567-7|pages=138–}}</ref><ref name="Shorter2008">{{cite book|author=Edward Shorter|title=Before Prozac : The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry|url=http://books.google.com/books?id=8VaYF8pIPxgC&pg=PA137|date=28 September 2008|publisher=Oxford University Press|isbn=978-0-19-970933-5|pages=137–}}</ref> | '''Nialamide''' ('''Niamid''', '''Niamide''', '''Nuredal''', '''Surgex''') is a non-selective, [[irreversible_inhibition|irreversible]] [[monoamine oxidase inhibitor]] (MAOI) of the [[hydrazine]] class that was used as an [[antidepressant]].<ref name="Publishing2006">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=http://books.google.com/books?id=_J2ti4EkYpkC&pg=PA2935|date=1 December 2006|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=2935–}}</ref> It was withdrawn by [[Pfizer]] several decades ago due to the risk of [[hepatotoxicity]].<ref name="Gad2012">{{cite book|author=Shayne C. Gad|title=Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition|url=http://books.google.com/books?id=AHA2g-qq6WwC&pg=PA138|date=26 April 2012|publisher=CRC Press|isbn=978-1-4398-4567-7|pages=138–}}</ref><ref name="Shorter2008">{{cite book|author=Edward Shorter|title=Before Prozac : The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry|url=http://books.google.com/books?id=8VaYF8pIPxgC&pg=PA137|date=28 September 2008|publisher=Oxford University Press|isbn=978-0-19-970933-5|pages=137–}}</ref> | ||
==References== | ==References== | ||
| Line 18: | Line 11: | ||
{{Antidepressants}} | {{Antidepressants}} | ||
[[Category:Monoamine oxidase inhibitors]] | [[Category:Monoamine oxidase inhibitors]] | ||
[[Category:Pyridines]] | [[Category:Pyridines]] | ||
[[Category:Amides]] | [[Category:Amides]] | ||
[[Category:Withdrawn drugs]] | [[Category:Withdrawn drugs]] | ||
[[Category:Drug]] | [[Category:Drug]] | ||
Revision as of 14:11, 8 April 2015
|
WikiDoc Resources for Nialamide |
|
Articles |
|---|
|
Most recent articles on Nialamide |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Nialamide at Clinical Trials.gov Clinical Trials on Nialamide at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Nialamide
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Nialamide Discussion groups on Nialamide Directions to Hospitals Treating Nialamide Risk calculators and risk factors for Nialamide
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Nialamide |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Nialamide (Niamid, Niamide, Nuredal, Surgex) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant.[1] It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.[2][3]
References
- ↑ William Andrew Publishing (1 December 2006). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
- ↑ Shayne C. Gad (26 April 2012). Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition. CRC Press. pp. 138–. ISBN 978-1-4398-4567-7.
- ↑ Edward Shorter (28 September 2008). Before Prozac : The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press. pp. 137–. ISBN 978-0-19-970933-5.